Section Arrow
HALO.NASDAQ
- Halozyme Therapeutics
Quotes are at least 15-min delayed:2024/12/26 02:06 EST
Last
 47.54
+0.38 (+0.81%)
Day High 
47.63 
Prev. Close
47.16 
1-M High
50 
Volume 
308.68K 
Bid
46
Ask
48.5
Day Low
46.755 
Open
47.25 
1-M Low
46.26 
Market Cap 
6.00B 
Currency USD 
P/E 15.62 
%Yield -- 
10-SMA 47.72 
20-SMA 48.03 
50-SMA 50.88 
52-W High 65.5327 
52-W Low 33.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.02/4.36
Enterprise Value
7.50B
Balance Sheet
Book Value Per Share
3.56
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
829.25M
Operating Revenue Per Share
6.14
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed:2024/12/26 02:06 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.